Literature DB >> 20449623

Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing.

Dolunay Gülmez1, Aslı Cakar, Burçin Sener, Jale Karakaya, Gülşen Hasçelik.   

Abstract

Accurate determination of resistance is important to ensure appropriate antimicrobial therapy in Stenotrophomonas maltophilia infections. This study was undertaken to evaluate the susceptibility results obtained by disc diffusion, E-test, Phoenix system, and reference agar dilution method and also to evaluate the in vitro activity of various antimicrobial combinations against multidrug-resistant S. maltophilia. Susceptibilities to several antimicrobial agents were determined by agar dilution, disc diffusion, and E-test according to the US Clinical Laboratory and Standards Institute (CLSI) guidelines. Results were also evaluated in the in Phoenix system for available agents. Twelve different antibiotic combinations were tested for synergy by the E-test method. Most synergic combinations were confirmed by microdilution checkerboard assay. Tigecycline, trimethoprim/sulfamethoxazole (TMP-SMX) and doxycycline were the most effective drugs against S. maltophilia. Poorest agreement was determined by disc diffusion and E-test against ticarcillin/clavulanate and ciprofloxacin (κ < 0.4), by disc diffusion against colistin (κ < 0.4), and by the Phoenix system against piperacillin/tazobactam (κ < 0.4). Based on these data, disc diffusion seems to be unreliable for ticarcillin/clavulanate, ciprofloxacin, and colistin; E-test for ticarcillin/clavulanate and ciprofloxacin; and the Phoenix system for piperacillin/tazobactam for S. maltophilia susceptibility testing. Synergistic activity was detected predominantly with TMP-SMX + ticarcillin/clavulanate and TMP-SMX + ceftazidime. TMP-SMX + ceftazidime synergy was also supported by the checkerboard method. However, TMP-SMX + ticarcillin/clavulanate combination revealed indifferent effect by the checkerboard assay. As ticarcillin/clavulanate and ciprofloxacin E-test results were beyond the acceptable correlation limits, synergy testing performed with these agents was considered as unreliable. Further studies are required to standardize susceptibility testing, especially for colistin, ticarcillin/clavulanate, and ciprofloxacin for S. maltophilia. TMP-SMX-containing drug combinations seemed to be more synergistic on multidrug-resistant S. maltophilia; however, these results merit further evaluation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20449623     DOI: 10.1007/s10156-010-0068-2

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  15 in total

1.  Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia.

Authors:  J W Betts; L M Phee; N Woodford; D W Wareham
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-04-30       Impact factor: 3.267

Review 2.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

Review 3.  Clinical challenges treating Stenotrophomonas maltophilia infections: an update.

Authors:  Maria F Mojica; Romney Humphries; John J Lipuma; Amy J Mathers; Gauri G Rao; Samuel A Shelburne; Derrick E Fouts; David Van Duin; Robert A Bonomo
Journal:  JAC Antimicrob Resist       Date:  2022-05-05

4.  Evaluation of colistin susceptibility in multidrug-resistant clinical isolates from cystic fibrosis, France.

Authors:  S Biswas; J-C Dubus; M Reynaud-Gaubert; N Stremler; J-M Rolain
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-05-30       Impact factor: 3.267

5.  A Combination of Trimethoprim-sulfamethoxazole and Ceftazidime Showed Good In Vitro Activity against Stenotrophomonas maltophilia.

Authors:  Nabilah Ismail; Zarifah Zam; Siti Asma Hassan; Zaidah Abdul Rahman
Journal:  Malays J Med Sci       Date:  2017-04-14

6.  Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome.

Authors:  George Samonis; Drosos E Karageorgopoulos; Sofia Maraki; Panagiotis Levis; Dimitra Dimopoulou; Nikolaos A Spernovasilis; Diamantis P Kofteridis; Matthew E Falagas
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

7.  Minimal Inhibitory Concentration of Ceftazidime and Co-trimoxazole for Stenotrophomonas Maltophilia using E-test.

Authors:  Firoozeh Jamali; Mohammad Ali Boroumand; Farzad Yazdani; Maryam Sotoudeh Anvari; Leila Pourgholi; Saeede Mahfouzi; Mohammad Khak
Journal:  J Glob Infect Dis       Date:  2011-07

8.  Antimicrobial susceptibility of stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates.

Authors:  Hae-Sun Chung; Seong Geun Hong; Young Ree Kim; Kyeong Seob Shin; Dong Hee Whang; Jee Young Ahn; Yeon-Joon Park; Young Uh; Chulhun L Chang; Jong Hee Shin; Hye Soo Lee; Kyungwon Lee; Yunsop Chong
Journal:  J Korean Med Sci       Date:  2013-01-08       Impact factor: 2.153

Review 9.  Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options.

Authors:  Ya-Ting Chang; Chun-Yu Lin; Yen-Hsu Chen; Po-Ren Hsueh
Journal:  Front Microbiol       Date:  2015-09-02       Impact factor: 5.640

Review 10.  Infections Caused by Stenotrophomonas maltophilia in Recipients of Hematopoietic Stem Cell Transplantation.

Authors:  Khalid Ahmed Al-Anazi; Asma M Al-Jasser
Journal:  Front Oncol       Date:  2014-08-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.